# 21 CFR Part 26, Subpart A—Specific Sector Provisions for Pharmaceutical Good Manufacturing Practices

21 CFR Part 26, Subpart A—Specific Sector Provisions for Pharmaceutical Good Manufacturing Practices, “Specific Sector Provisions for Pharmaceutical Good Manufacturing Practices”, is a CFR division of [21 CFR Part 26—Mutual recognition of pharmaceutical good manufacturing practice reports, medical device quality system audit reports, and certain medical device product evaluation reports: United States and the European Community](https://ontology.bommaritollc.com/id/01a0f094-b7ef-7601-a5d1-ac01dec9bdba).

IRI: <https://ontology.bommaritollc.com/id/01a0f094-b4ba-778d-86dc-989054e0de2d>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter A—GENERAL](https://ontology.bommaritollc.com/id/01a0f094-b456-7008-a83b-fa94ddeea764) › [21 CFR Part 26—Mutual recognition of pharmaceutical good manufacturing practice reports, medical device quality system audit reports, and certain medical device product evaluation reports: United States and the European Community](https://ontology.bommaritollc.com/id/01a0f094-b7ef-7601-a5d1-ac01dec9bdba)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-division 21 CFR Part 26, Subpart A](https://ontology.bommaritollc.com/id/01a0f094-b4bb-7230-b547-b03a3038c14a)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol1](https://ontology.bommaritollc.com/id/01a0f094-b4ba-778d-86dc-988f23f9ffbb)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-d902-7534-8f13-c63393af6749)
- `schema:isPartOf`: [21 CFR Part 26—Mutual recognition of pharmaceutical good manufacturing practice reports, medical device quality system audit reports, and certain medical device product evaluation reports: United States and the European Community](https://ontology.bommaritollc.com/id/01a0f094-b7ef-7601-a5d1-ac01dec9bdba)
- `schema:legislationIdentifier`: 21 CFR Part 26, Subpart A
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationType`: [CFR division](https://ontology.bommaritollc.com/vocab/leg/cfrDivision)
- `schema:name`: Specific Sector Provisions for Pharmaceutical Good Manufacturing Practices
- `skos:prefLabel`: 21 CFR Part 26, Subpart A—Specific Sector Provisions for Pharmaceutical Good Manufacturing Practices

## Elsewhere

- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol1) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Parts (26; `schema:isPartOf`):
  - [21 CFR 26.1 Definitions.](https://ontology.bommaritollc.com/id/01a0f094-bb9f-72ba-a488-d0ddda276900)
  - [21 CFR 26.10 Regulatory authorities not listed as currently equivalent.](https://ontology.bommaritollc.com/id/01a0f094-bba6-7206-b2a1-4a1841580ff6)
  - [21 CFR 26.11 Start of operational period.](https://ontology.bommaritollc.com/id/01a0f094-bba7-748a-82d8-2067226d6df6)
  - [21 CFR 26.12 Nature of recognition of inspection reports.](https://ontology.bommaritollc.com/id/01a0f094-bba8-7751-8fd6-c3121035134a)
  - [21 CFR 26.13 Transmission of postapproval inspection reports.](https://ontology.bommaritollc.com/id/01a0f094-bba8-7751-8fd6-c320727a9e92)
  - [21 CFR 26.14 Transmission of preapproval inspection reports.](https://ontology.bommaritollc.com/id/01a0f094-bba9-71bd-a4a0-434ff8b0bde5)
  - [21 CFR 26.15 Monitoring continued equivalence.](https://ontology.bommaritollc.com/id/01a0f094-bbaa-742c-853f-8ba44bcfb511)
  - [21 CFR 26.16 Suspension.](https://ontology.bommaritollc.com/id/01a0f094-bbab-7146-af2a-83915782bd11)
  - [21 CFR 26.17 Role and composition of the Joint Sectoral Committee.](https://ontology.bommaritollc.com/id/01a0f094-bbac-7625-84ae-07f80d36f599)
  - [21 CFR 26.18 Regulatory collaboration.](https://ontology.bommaritollc.com/id/01a0f094-bbac-7625-84ae-0806f387082c)
  - [21 CFR 26.19 Information relating to quality aspects.](https://ontology.bommaritollc.com/id/01a0f094-bbad-7600-8e8c-735a2164fcce)
  - [21 CFR 26.2 Purpose.](https://ontology.bommaritollc.com/id/01a0f094-bba0-77ad-99f2-c7c8622a08c0)
  - [21 CFR 26.20 Alert system.](https://ontology.bommaritollc.com/id/01a0f094-bbae-721c-a0fb-daeb418c6e71)
  - [21 CFR 26.21 Safeguard clause.](https://ontology.bommaritollc.com/id/01a0f094-bbaf-72a1-905e-0d092078ad69)
  - [21 CFR 26.3 Scope.](https://ontology.bommaritollc.com/id/01a0f094-bba0-77ad-99f2-c7d52bf8be70)
  - [21 CFR 26.4 Product coverage.](https://ontology.bommaritollc.com/id/01a0f094-bba1-738d-8e8a-f2ec8e7ce694)
  - [21 CFR 26.5 Length of transition period.](https://ontology.bommaritollc.com/id/01a0f094-bba2-73a2-8707-dc14f63b786b)
  - [21 CFR 26.6 Equivalence assessment.](https://ontology.bommaritollc.com/id/01a0f094-bba3-741c-a161-c15a92926f09)
  - [21 CFR 26.7 Participation in the equivalence assessment and determination.](https://ontology.bommaritollc.com/id/01a0f094-bba4-721a-b4b9-cf419f2dce8b)
  - [21 CFR 26.8 Other transition activities.](https://ontology.bommaritollc.com/id/01a0f094-bba5-70f3-bc09-7e6fdb4c41e2)
  - [21 CFR 26.9 Equivalence determination.](https://ontology.bommaritollc.com/id/01a0f094-bba5-70f3-bc09-7e7ddaccf814)
  - [21 CFR Appendix A to Subpart A of Part 26 List of Applicable Laws, Regulations, and Administrative Provisions](https://ontology.bommaritollc.com/id/01a0f094-bbb0-7278-ae2f-95261ab03d89)
  - [21 CFR Appendix B to Subpart A of Part 26 List of Authorities](https://ontology.bommaritollc.com/id/01a0f094-bbb0-7278-ae2f-95343cbfb1f2)
  - [21 CFR Appendix C to Subpart A of Part 26 Indicative List of Products Covered by Subpart A](https://ontology.bommaritollc.com/id/01a0f094-bbb1-723e-9470-5c6f1ffd8a0f)
  - [21 CFR Appendix D to Subpart A of Part 26 Criteria for Assessing Equivalence for Post- and Preapproval](https://ontology.bommaritollc.com/id/01a0f094-bbb2-76cc-813a-4b1189641f14)
  - [21 CFR Appendix E to Subpart A of Part 26 Elements To Be Considered in Developing a Two-Way Alert System](https://ontology.bommaritollc.com/id/01a0f094-bbb3-7394-8201-5156f2ba8027)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-b4ba-778d-86dc-989054e0de2d.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-b4ba-778d-86dc-989054e0de2d.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-b4ba-778d-86dc-989054e0de2d.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-b4ba-778d-86dc-989054e0de2d)
Cite as: 21 CFR Part 26, Subpart A—Specific Sector Provisions for Pharmaceutical Good Manufacturing Practices. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-b4ba-778d-86dc-989054e0de2d
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
